Evolve Additive Solutions Enhances Production Portfolio with New Global Parts Service and Two New Materials
8.11.2023 08:00:00 CET | Business Wire | Press Release
Evolve Additive Solutions, provider of industrial 3D printing solutions, announced today at Formnext the commercial launch of its all-new parts production service, STEP Parts Now, as well as an expansion of its materials portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231102395276/en/
ABS Check Valves / Image credit: Evolve Additive Solutions
STEP Parts Now
Meeting production demand, along with Evolve’s drive to broaden access to its Selective Thermoplastic Electrophotographic Process (STEP™) technology, spurred the creation of the new parts production service. STEP is the only additive manufacturing (AM) process in the market today that can deliver on the fidelity, surface finish, accuracy, and material properties required to reliably and repeatably print end-use parts at scale.
Customers can now quote and order STEP parts directly from Evolve through the STEP Parts Now e-commerce portal.
STEP Parts Now complements part ordering availability through Evolve’s strategic partners and their STEP production centers: Fathom Digital Manufacturing based in the US, and alphacam Gmbh based in Germany. Customers now have additional options in their pursuit of additive manufactured parts from prototype through production.
“What we are launching with STEP Parts Now is much more than parts as a service,” said Jeff Hanson, Evolve’s Senior Vice President of Go-to-Market. “We are increasing accessibility to a newly identified additive manufacturing technology category that finally delivers on past industry promises of materials, features, and scalability by additive manufacturing for true production.”
Expanded Materials Portfolio
In addition to its launch of STEP Parts Now, Evolve has announced the commercial availability of two new materials in its portfolio: Nylon PA-11(A) and Gray ABS.
Evolve’s PA-11(A) for STEP offers significant mechanical performance advantages over powder bed fusion PA-11. Qualities including a superior elongation at break, higher impact strength, and a higher heat deflection temperature (HDT) make Evolve’s PA-11(A) parts usable in more demanding production applications.
The new Gray ABS material complements Evolve’s existing Black ABS and exhibits mechanical properties within 10% of bulk injection molded ABS. Additionally, it exhibits impressive structural color contrast for fine features and textures.
Evolve is showcasing its STEP Parts Now and new material offerings this week at Formnext in hall 12.1 at booth B-89. Full details will be available from the Evolve team including Jeff Blank, President, and COO; Jeff Hanson, SVP of Go-to-Market; and Melissa Hanson, VP Marketing at a press conference to be held on-site at Formnext today, November 8, 14:00-15:00 in the Portalhaus, Level C, Room Prisma.
Schedule a meeting here with the Evolve team during the event.
About Evolve Additive Solutions
Evolve Additive Solutions is transforming how the world manufactures. Founded in 2017, the company offers additive manufacturing production equipment, materials, software, parts production, and application and consulting services. Evolve allows for manufacturing flexibility, creating uniquely functional products while increasing speed to market and efficiency securing supply chains. Evolve’s patented STEP technology is able to efficiently produce commercial grade production parts and create unique products that cannot be manufactured with traditional methods. The company is headquartered in Minnetonka, MN with a materials technology center based in Rochester, NY. More at: www.evolveadditive.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231102395276/en/
Contact information
Cheryl Hillman
Sr. Marketing Manager, Evolve Additive Solutions
cheryl.hillman@evolveadditive.com
+1 (763) 438-6569
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press Release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom